An interventional study of Non-surgical periodontal treatment in Atherosclerosis, Endothelial Dysfunction and Peri-Implantitis, sponsored by University of Catania. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by University of Catania · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Atherosclerosis with a site in Italy — 12 open to participants now, 22 under way, 10 of them phase 3. Atherosclerosis · Italy.
Among the 81 studies in Atherosclerosis with a site in Italy, this one is the 37th largest by planned enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2020, is one of 20 with no phase, reaches primary completion later than 4 of the 21 other live ones, and was the 63rd registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →12 of the 81 studies in Atherosclerosis with a site in Italy are open now. Recruiting first, the newest first:
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Sites in Italy, France, Netherlands and 1 more country
Ages 12+
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Sites in Italy
Ages 40–70 · Healthy volunteers
Eli Lilly and Company · Sites in Italy, United States, Argentina and 25 more countries
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 33 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 20 · Phase 4 6
First in 1996; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 423 across the 51 interventional studies, 312 across the 29 observational. Of the 43 that completed or were terminated, 15 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 81 have an industry lead sponsor. The 10 most frequent:
University of Catania is the lead sponsor of 71 studies on the registry; 15 are open to participants now.
University of Catania has 2 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Atherosclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06230406IRCCS Policlinico S. DonatoT-Mem GEne in Atherosclerosis | 2026-12 |
| NCT07352111I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioHigh-risk Coronary Atherosclerosis in Subjects With Family History of Myocardial Infarction | 2026-12-31 |
| NCT07447648Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 81 studies in Atherosclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with peri-implantitis/peri-implant mucositis and without any cardiovascular disease.
A double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with peri-implantitis/peri-implant mucositis and without any cardiovascular disease.
90 patients: 30 with peri-implantitis, 30 with peri-implant mucositis and 30 healthy controls and without periodontitis history.
All the patients are assessed for clinical, periodontal, blood and non-invasive ultrasound cardiovascular parameters. Measurements are taken before and after initial periodontal treatment in the peri-implantitis/peri-implant mucositis subjects.
PERI-IMPLANTITIS GROUP
Inclusion Criteria:
Exclusion Criteria:
PERI-IMPLANT MUCOSITIS GROUP
Inclusion Criteria:
Exclusion Criteria:
HEALTHY GROUP
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects diagnosed with peri-implantitis according to the most recent international guidelines and without cardiovascular diseases.
Procedure: Non-surgical periodontal treatment
Subjects diagnosed with peri-implant mucositis according to the most recent international guidelines and without cardiovascular diseases.
Procedure: Non-surgical periodontal treatment
Subjects without periodontitis and with good gingival health.
Subgingival biofilm ultrasonic debridement
Pulse Wave Velocity carotid-femoral (PWV-CF)
The speed of pulse wave propagation between carotid-femoral sites
Time frame: 8 weeks
Pulse Wave Velocity carotid-femoral (PWV-CR)
The speed of pulse wave propagation between carotid-radial sites
Time frame: 8 weeks
Carotid Intima-Media Thickness (CIMT)
The thickness of the carotid intima and media
Time frame: 8 weeks
Distensibility Coefficient (DC)
The relative change in luminal area during systole for a given pressure change (pulsed pressure), will be calculated assuming the lumen to be circular.
Time frame: 8 weeks
Advanced Glycation End products (AGEs)
A group of endogenous heterogeneous compounds that are constantly formed under physiological conditions with prooxidant and cytotoxic properties. Measurements are performed by fluorescence spectroscopy technique.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Nov 2025, 61 months after the start.
Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 61 months is above that.
Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Catania